Reporte zur Charge EN9318

Symptomtext

has COVID; has COVID; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 64-year-old female patient received BNT162b2 (BNT162B2), on 08Jan2021 as dose 1, single (Lot number: EL3246), in left arm and on 29Jan2021 as dose 2, single (Lot number: EN9318) at the age of 62 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "allergic to peg" (unspecified if ongoing), notes: allergic to peg. The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant), outcome "unknown" and all described as "has COVID". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Unknown, notes: Not Provided. Therapeutic measures were not taken as a result of drug ineffective, suspected covid-19. Clinical course: Patient had not taken Paxlovid because Paxlovid was coated in peg, polyethylene glycol. Paxlovid: Dose: Was provided the 300mg-100mg dose pack. Each dose pack has two Nirmatrelvir 150mg and 1 Ritonavir 100mg in the blister packs for morning and night dose. Caller clarified caller has not administered any of the Paxlovid. Received first and second dose of Adult Covid Vaccine and had COVID. Thinks was allergic to Polyethylene glycol, ingredient in the Adult COVID Vaccine. In past, has had reactions to other pharmaceuticals. Other pharmaceutical names not provided. Polyethylene glycol is an ingredient in the Adult COVID Vaccine, is a carrier. No follow-up attempts were possible. No further information was expected.